| 英文名稱 | Protopanaxatriol |
|---|---|
| 中文名稱 | 原人參三醇/20(S)-原人參三醇/(S型)原人參三醇/S-原人參三醇/(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-((S)-2-羥基-6-甲基庚-5-烯-2-基)-4,4,8,10,14-五甲基十六氫-1H-環(huán)戊[a]菲-3,6,12-三醇 |
| CAS號(hào) | 34080-08-5 |
| 分子式 | C30H52O4 |
| 分子量 | 476.73 |
| 外觀 | 白色結(jié)晶粉末 |
| 熔點(diǎn) | 242-244 °C |
| 沸點(diǎn) | 590.0±50.0 °C | Condition: Press: 760 Torr |
| 酸度系數(shù)pKa | 14.73±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000703
中文名稱：原人參三醇
中文別名：20(S)-原人參三醇；(S型)原人參三醇；S-原人參三醇；(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-((S)-2-羥基-6-甲基庚-5-烯-2-基)-4,4,8,10,14-五甲基十六氫-1H-環(huán)戊[a]菲-3,6,12-三醇
英文名稱：Protopanaxatriol
英文別名：Dammar-24-ene-3β,6α,12β,20-tetrol, (20S)- (8CI);(3β,6α,12β)-Dammar-24-ene-3,6,12,20-tetrol;(20S)-Protopanaxatriol;20(S)-APPT;Panaxoside A aglycone Aφ;
分子式：C30H52O4
分子量：476.73
CAS號(hào)：34080-08-5
純度：HPLC≥98%
熔點(diǎn)：242-244 °C
沸點(diǎn)：590.0±50.0 °C | Condition: Press: 760 Torr
密度：1.079±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：14.73±0.70 | Condition: Most Acidic Temp: 25 °C
儲(chǔ)存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標(biāo)準(zhǔn)品和天然植物有效單體，主打中藥對照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
| Effect of ninjin’yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice | ||
| 來源：SCI：Journal of Natural Medicines | 作者：Suzuki, Toshiaki | 備注：影響因子：1.982 |
| 引用描述 | ||
The water layer was further partitioned with water-saturated BuOH three times, yielding the BuOH and water fractions (0.20 and 4.4 g, respectively). Ginsenosides F1, F2, Rd, Rg3, Rh1, Rh2, protopanaxadiol, and protopanaxatriol were obtained from Sichuan Weikeqi Biological Technology (Chengdu, Sichuan, China); ginsenosides Rg1 and Rb1 were obtained from Wako Pure Chemical Industries (Osaka, Japan) | ||
| Ginsenosides, ingredients of the root of Panax ginseng, are not substrates but inhibitors of sodium-glucose transporter 1 | ||
| 來源：SCI：Journal of Natural Medicines | 作者：Gao, Shengli | 備注：影響因子：1.67 |
| 引用描述 | ||
Ginsenosides Rg1 and Rb1 were obtained from Wako Pure Reagents (Osaka). Compound K was obtained from ChromaDex (Irvine, CA, USA). Ginsenosides F1, F2, Rd, Rg3, Rh1, Rh2, protopanaxadiol and protopanaxatriol were obtained from Sichuan Weikeqi Biological Technology (Chengdu, Sichuam, China). Chemical structures of ginsenosides used in the present study are shown in Fig. 1. | ||
| Structure–inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs) | ||
| 來源：SCI：TOXICOLOGY AND APPLIED PHARMACOLOGY | 作者：Zhong-Ze Fang | 備注：影響因子：3.975 |
| 引用描述 | ||
Recombinant human UGT isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, UGT2B15) expressed in baculovirus-infected insect cells were obtained from BD Gentest Corp. (Woburn, MA, USA). Ginsenosides Rb1, Rb2, Rc, Rd, Rg3, Rh2, C-K, ppd, ppt, Re, Rg1, Rh1, F1, and F2 were purchased from Sichuan Weikeqi Biotechnology Company (Chengdu, Sichuan, China). The purity of these compounds was above 95%. All other reagents were of HPLC grade or of the highest grade commercially available. | ||
